Cell therapy for pancreatic cancer: MUC1-specific cytotoxic T cell and MUC1 mRNA introduction dendritic cell therapy

Yoshinari Maeda, Shoichi Hazama, Shin Yoshida, Kazunari Maeda, Yuka Sonoda, Yuko Yanai, Kiyoshi Yoshimura, Michihisa Iida, Nobuaki Suzuki, Tomio Ueno, Shigefumi Yoshino, Masaaki Oka

Research output: Contribution to journalArticlepeer-review

Abstract

MUC1 is a tumor-associated antigen that is overexpressed in invasive ductal carcinomas of the pancreas (PC). MUC1-specific cytotoxic T lymphocytes (CTLs) recognize MUC1 molecules in an HLA-unrestricted manner. We have reported the efficacy of adoptive immunotherapy (AIT) with CTLs stimulated by autologous pancreatic tumors and vaccination with a variety of peptides. We also have reported the use of AIT with CTLs (MUC1-CTLs)stimulated by an MUC1-expressing human pancreatic cancer cell line, YPK-1. AIT with MUC1-CTLs for unresectable pancreatic cancer did not improve survival, although no patient without liver metastasis developed liver metastasis during the study. To overcome these limitations, we developed an AIT using a combination of MUC1-CTLs and dendritic cells (DCs) pulsed with MUC1-peptide. This AIT showed good results. In our next study, we are planning AIT with MUC1-CTLs and DCs transfected with MUC1-mRNA for unresectable PC.

Original languageEnglish (US)
Pages (from-to)105-110
Number of pages6
JournalBiotherapy
Volume24
Issue number2
StatePublished - Mar 2010
Externally publishedYes

Keywords

  • Bectroporation
  • Immunotherapv
  • MUC1
  • Pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Cell therapy for pancreatic cancer: MUC1-specific cytotoxic T cell and MUC1 mRNA introduction dendritic cell therapy'. Together they form a unique fingerprint.

Cite this